Kurs
-3,49%
Likviditet
10,1 MSEK
Prenumeration
Kalender
Est. tid* | ||
2026-02-12 | 07:30 | Bokslutskommuniké 2025 |
2025-10-22 | 07:30 | Kvartalsrapport 2025-Q3 |
2025-07-23 | 07:30 | Kvartalsrapport 2025-Q2 |
2025-04-25 | - | X-dag ordinarie utdelning SECARE 0.25 SEK |
2025-04-24 | - | Årsstämma |
2025-04-24 | - | Kvartalsrapport 2025-Q1 |
2025-02-13 | - | Bokslutskommuniké 2024 |
2024-10-23 | - | Kvartalsrapport 2024-Q3 |
2024-07-25 | - | Kvartalsrapport 2024-Q2 |
2024-04-26 | - | X-dag ordinarie utdelning SECARE 0.23 SEK |
2024-04-25 | - | Årsstämma |
2024-04-25 | - | Kvartalsrapport 2024-Q1 |
2024-02-15 | - | Bokslutskommuniké 2023 |
2023-10-25 | - | Kvartalsrapport 2023-Q3 |
2023-07-27 | - | Kvartalsrapport 2023-Q2 |
2023-05-02 | - | X-dag ordinarie utdelning SECARE 0.22 SEK |
2023-04-28 | - | Årsstämma |
2023-04-28 | - | Kvartalsrapport 2023-Q1 |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-10-27 | - | Kvartalsrapport 2022-Q3 |
2022-10-19 | - | Extra Bolagsstämma 2022 |
2022-07-28 | - | Kvartalsrapport 2022-Q2 |
2022-05-12 | - | Kvartalsrapport 2022-Q1 |
2022-04-29 | - | X-dag ordinarie utdelning SECARE 0.20 SEK |
2022-04-28 | - | Årsstämma |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-10-28 | - | Kvartalsrapport 2021-Q3 |
2021-07-29 | - | Kvartalsrapport 2021-Q2 |
2021-05-24 | - | Split SECARE 1:5 |
2021-04-30 | - | X-dag ordinarie utdelning SECARE 0.80 SEK |
2021-04-29 | - | Årsstämma |
2021-04-29 | - | Kvartalsrapport 2021-Q1 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-10-22 | - | Kvartalsrapport 2020-Q3 |
2020-09-11 | - | Extra Bolagsstämma 2020 |
2020-07-24 | - | Kvartalsrapport 2020-Q2 |
2020-04-22 | - | X-dag ordinarie utdelning SECARE 0.70 SEK |
2020-04-21 | - | Årsstämma |
2020-04-21 | - | Kvartalsrapport 2020-Q1 |
2020-02-13 | - | Bokslutskommuniké 2019 |
2019-10-24 | - | Kvartalsrapport 2019-Q3 |
2019-07-26 | - | Kvartalsrapport 2019-Q2 |
2019-04-26 | - | X-dag ordinarie utdelning SECARE 0.00 SEK |
2019-04-25 | - | Årsstämma |
2019-04-25 | - | Kvartalsrapport 2019-Q1 |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-10-25 | - | Kvartalsrapport 2018-Q3 |
2018-07-27 | - | Kvartalsrapport 2018-Q2 |
2018-04-26 | - | Kvartalsrapport 2018-Q1 |
2018-04-25 | - | X-dag ordinarie utdelning SECARE 0.00 SEK |
2018-04-24 | - | Årsstämma |
2018-02-22 | - | Bokslutskommuniké 2017 |
2017-10-26 | - | Kvartalsrapport 2017-Q3 |
2017-08-25 | - | Kvartalsrapport 2017-Q2 |
2017-04-28 | - | X-dag ordinarie utdelning SECARE 0.00 SEK |
2017-04-27 | - | Årsstämma |
2017-04-27 | - | Kvartalsrapport 2017-Q1 |
2017-02-16 | - | Bokslutskommuniké 2016 |
2016-10-27 | - | Kvartalsrapport 2016-Q3 |
2016-08-25 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
The extraordinary general meeting (EGM) of Swedencare AB (publ) took place on Wednesday, 19 October 2022. The extraordinary general meeting was conducted by postal voting, without physical attendance. Complete information and documentation regarding the EGM's decision can be found on the company's website, www.swedencare.com. The EGM resolved in line with all of the motions presented in the notification of the EGM.
Resolution regarding incentive program, comprising a private placement and assignment of warrants
The EGM resolved, in accordance with the Board’s proposal, on an incentive program for employees in the Swedencare Group, comprising a private placement of not more than 415,000 warrants to the company and assignment of warrants to the participants in the incentive program. The transfer of the warrants to the participants in the incentive program shall take place at market value.
Each warrant entitles the holder, during the period from 1 December 2025 to 28 February 2026, to subscribe for one (1) new share in Swedencare at a subscription price amounting to 135 percent of the volume-weighted average price paid for the company's share on Nasdaq First North Growth Market during the period from 12 October 2022 to 18 October 2022. The company’s share capital can increase by a maximum of SEK 4,150 which corresponds to a dilution effect of at most about 0.26 percent.
For more information, please contact:
Håkan Lagerberg, CEO Swedencare
Phone: +46 (0)73 517 01 70
Email: hakan.lagerberg@swedencare.se
Jenny Graflind, CFO Swedencare
Phone: +46 (0)73 944 85 54
Email: jenny.graflind@swedencare.se
FNCA is the Certified Adviser of the Company
Please visit the Company homepage www.swedencare.com
About Swedencare
Swedencare, a listed company on NASDAQ First North Growth Market, specializes in pet healthcare and produces, markets and sells premium products in the global and fast-growing market. The company has a wide range of strong brands and products within most therapy areas, including Animal Pharmaceuticals®, Nutravet®, NutriScience, Pet MD®, Stratford®, VetWELL®, NaturVet® as well as ProDen PlaqueOff® for oral health to dogs and cats. Swedencare’s headquarter is in Malmö, Sweden with subsidiaries located in nine countries with products sold in more than sixty countries. Swedencare’s sales have increased significantly over the last few years with strong margins and profits.